Objectives To update and assess the efficacy and tolerability of once weekly subcutaneous
semaglutide in patients with type 2 diabetes (T2D). Materials and methods PubMed, Science …

Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …

Background and aims Oral semaglutide has undergone global Phase 3 development
programs named PIONEER and approved for therapeutic use in people with type 2 diabetes …

Background: This meta-analysis aimed to combine the data available from clinical trials to
assess the effects of subcutaneous and oral semaglutide administration on glycemic control …

Background: It is a great challenge for type 2 diabetes mellitus (T2DM) patients to maintain
optimal glycemia, control body weight, blood pressure, and avoiding hypoglycemia …

Objectives To investigate the efficacy and safety of oral semaglutide 7 and 14 mg, the only
orally delivered glucagon-like peptide-1 (GLP-1) receptor agonist tablet approved for type 2 …

Importance Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the
treatment of type 2 diabetes and are all currently available as an injection. Objectives To …

Aims To assess the efficacy and safety of semaglutide, a recently approved glucagon‐like
peptide 1 receptor agonist (GLP‐1 RA) for type 2 diabetes. Materials and methods We …

Introduction: Type 2 diabetes is a chronic metabolic disease characterized by persistent
hyperglycemia resulting from progressive deficient of insulin in patients with a background of …

Aim Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA)
indicated for glycaemic management in adults with type 2 diabetes (T2D). Oral semaglutide …